Skip to content

The Telegraph: Three-parent babies: House of Lords approves law despite fears children could be born sterile

The House of Lords has approved controversial IVF procedures aimed at preventing inherited mitochondrial diseases Peers have approved historic legislation which would see Britain become the first country in the world to create three-parent babies, despite fears children could be born sterile.  MORE… 

Bloomberg: Biotech Has Surged Massively Since Warning From the Fed

Investors are kicking themselves if they listened to Fed Chair Janet Yellen and the Board of Governors last July and sold their biotech stocks. As Bespoke Investment Group points out, the Nasdaq Biotech index is up well over 40 percent since Yellen’s valuation comments. Here is what the Fed said in its Monetary Policy Report…

Webinar: Using Social Media for Patient Recruitment in Clinical Trials

Using Social Media for Patient Recruitment in Clinical Trials REGISTER NOW Date: Wednesday, April 22, 2015 Time: 1pm EDT Duration: 90 Minutes Location: Live, interactive training on your computer Price: $299 – Includes slides, handouts, exam, and completion certificate! Course Description: By participating in this interactive 90-minute session, you will understand: How to craft a…

Twitter Strategies For Biotechs

From Biotech-now.org:  Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz andBrad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust,…

Cara is soaring!

Shares of Cara Therapeutics (NASDAQ:CARA) have been given an average broker rating score of 1.20 (Strong Buy) from the five brokers that providecoverage for the stock, Zacks Investment Researchreports. One equities research analyst has rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. Cara Therapeutics’ rating…

Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered…

Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

TARRYTOWN, N.Y. and PARIS, Jan. 26, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for PraluentTM (alirocumab). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is six…

Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy

SANTA MONICA, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR…

Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Feb. 2, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse™ for…

BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism Model

Hackensack, NJ & Petach Tikvah, Israel – January 26, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been induced, under…